Basic↦Ethics and Laws↦Clinical Trials Ordinance↦Gene Therapy, GMO, Pathogenic
What is it? Why is it important?
The Human Research Act (HRA) regulates through its Clinical Trials Ordinance (ClinO) studies of gene therapy, and genetically modified organisms (GMO), or pathogenic organisms.
Studies using:
- Gene therapy: are studies in which genetic information is introduced into somatic cells (somatic gene therapy)
- Genetically modified organisms: are Medcinal Product (MP) studies using genetically modified organisms (e.g. as defined in the Release Ordinance (RO) on the handling of organisms in the environment)
- Pathogenic organisms: are MP studies using pathogenic organisms as defined in the RO
Study set-up and type will decide the risk-category of the study (e.g. risk-categories A, B, or C apply, with A having the lowest and C the highest risk). As applicable, the same provisions and risk categorisations as defined for MP studies apply.
What do I need to do?
As a SP-INV planning studies with genetically modified or pathogenic organisms, you are required to know and comply with the requirements defined in the ClinO ordinance:
- Familiarise yourself with the organisation of the various chapters and sections
- Focus on the articles that are relevant to your study
Based on the risk-category fo your study, submit your application dossier to:
- The Ethics Committee (e.g. EC, application dossier) who grants authorisation of risk-category A, B, and C studies, and provides a reply within:
- 30 days, for monocentric studies
- 45 days, for multi-centre studies
- The Swissmedic (e.g. application dossier) who grants authorisation of risk-category B and C studies, and provides a reply:
- Within 60 days
- After having received the opinions from SECB, FOPH, and FOEN
- For the duration of the study, but no longer than 5 years upon approval
- Risk-category A studies are exempt from Swissmedic authorisation
A Swissmedic submission and an EC submission must be done in parallel.
More
Swissmedic grants study authorisation if the:
- Swiss Expert Committee for Biosafety (SECB) confirms the quality and safety of the planned product (e.g. participant safety, human health, and environment)
- Federal Office of Public Health (FOPH) and Federal Office for the Environment (FOEN) raise no objections based on the assessment of environmental data
Swissmedic, FOPH and FOEN jointly assess and issue guidelines regarding
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
References
KOFAM: Coordination portal for human research – see in particular
- Online wizard for risk categorisation
RO - see in particular
- Art. 3 Definitions
FOEN – Federal Office for the Environment
SECB – Swiss Expert Committee for Biosafety
Swiss Law
ClinO – see in particular articles
- Art. 22 Definitions and categorisation of studies of gene therapy and genetically modified pathogenic organisms
- Art. 26 Procedures and deadlines EC
- Art. 27 Procedures and deadlines EC in multi-centre clinical trials
- Art. 33 Procedures and deadlines Swissmedic
- Art. 35 Special provisions